Cargando…
Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran
BACKGROUND: Understanding the reasons for loss to follow-up (LTFU) in cohort studies, especially among marginalized groups such as people who inject drugs (PWID), is needed to strengthen the rigor of efficacy trials for prevention and treatment interventions. We assessed the proportion and reasons f...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017615/ https://www.ncbi.nlm.nih.gov/pubmed/33794943 http://dx.doi.org/10.1186/s13011-021-00368-9 |
_version_ | 1783674084107747328 |
---|---|
author | Mousavian, Ghazal Ghalekhani, Nima Tavakoli, Fatemeh McFarland, Willi Shahesmaeili, Armita Sharafi, Heidar Khezri, Mehrdad Mehmandoost, Soheil Zarei, Jasem Sharifi, Hamid Mirzazadeh, Ali |
author_facet | Mousavian, Ghazal Ghalekhani, Nima Tavakoli, Fatemeh McFarland, Willi Shahesmaeili, Armita Sharafi, Heidar Khezri, Mehrdad Mehmandoost, Soheil Zarei, Jasem Sharifi, Hamid Mirzazadeh, Ali |
author_sort | Mousavian, Ghazal |
collection | PubMed |
description | BACKGROUND: Understanding the reasons for loss to follow-up (LTFU) in cohort studies, especially among marginalized groups such as people who inject drugs (PWID), is needed to strengthen the rigor of efficacy trials for prevention and treatment interventions. We assessed the proportion and reasons for loss to follow-up in a recent cohort of PWID enrolled in the southeast of Iran. METHODS: Using respondent-driven sampling, we recruited 98 PWID age 18 years or older who reported injecting drugs in the past 6 months, and were negative for HIV and HCV at initial screening. Participants were followed at 6 week intervals, alternating a short six-week visit and long 12-week or quarterly visit to measure incidence of HIV and HCV. Methods to enhance retention included incentives for completing each visit, tracking people who missed the scheduled visits through their peer referral networks, engaged outreach teams to explore hotspots and residences, and photos. LTFU was defined as participants who missed their quarterly visits for two or more weeks. RESULTS: Mean (SD) age of participants was 39.7 years (SD 9.6). Of 98 enrolled, 50 participants (51.0%) were LTFU by missed their scheduled quarterly visits for 2 weeks or more. For those whose reasons for LTFU could be defined (46.0%, 23 of 50), main reasons were: forgetting the date of visit (43.5%, 10 of 23), being incarcerated (39.1%, 9 of 23), and moving out of the city (17.4%, 4 of 23). CONCLUSION: This study highlighted the difficulty in retaining PWID in longitudinal studies. Despite having several retention strategies in place, over half of PWID were LTFU. The LTFU might be reduced by setting up more effective reminder systems, working closely with security systems, and online means to reach those who move outside the study area. |
format | Online Article Text |
id | pubmed-8017615 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80176152021-04-02 Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran Mousavian, Ghazal Ghalekhani, Nima Tavakoli, Fatemeh McFarland, Willi Shahesmaeili, Armita Sharafi, Heidar Khezri, Mehrdad Mehmandoost, Soheil Zarei, Jasem Sharifi, Hamid Mirzazadeh, Ali Subst Abuse Treat Prev Policy Research BACKGROUND: Understanding the reasons for loss to follow-up (LTFU) in cohort studies, especially among marginalized groups such as people who inject drugs (PWID), is needed to strengthen the rigor of efficacy trials for prevention and treatment interventions. We assessed the proportion and reasons for loss to follow-up in a recent cohort of PWID enrolled in the southeast of Iran. METHODS: Using respondent-driven sampling, we recruited 98 PWID age 18 years or older who reported injecting drugs in the past 6 months, and were negative for HIV and HCV at initial screening. Participants were followed at 6 week intervals, alternating a short six-week visit and long 12-week or quarterly visit to measure incidence of HIV and HCV. Methods to enhance retention included incentives for completing each visit, tracking people who missed the scheduled visits through their peer referral networks, engaged outreach teams to explore hotspots and residences, and photos. LTFU was defined as participants who missed their quarterly visits for two or more weeks. RESULTS: Mean (SD) age of participants was 39.7 years (SD 9.6). Of 98 enrolled, 50 participants (51.0%) were LTFU by missed their scheduled quarterly visits for 2 weeks or more. For those whose reasons for LTFU could be defined (46.0%, 23 of 50), main reasons were: forgetting the date of visit (43.5%, 10 of 23), being incarcerated (39.1%, 9 of 23), and moving out of the city (17.4%, 4 of 23). CONCLUSION: This study highlighted the difficulty in retaining PWID in longitudinal studies. Despite having several retention strategies in place, over half of PWID were LTFU. The LTFU might be reduced by setting up more effective reminder systems, working closely with security systems, and online means to reach those who move outside the study area. BioMed Central 2021-04-01 /pmc/articles/PMC8017615/ /pubmed/33794943 http://dx.doi.org/10.1186/s13011-021-00368-9 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Mousavian, Ghazal Ghalekhani, Nima Tavakoli, Fatemeh McFarland, Willi Shahesmaeili, Armita Sharafi, Heidar Khezri, Mehrdad Mehmandoost, Soheil Zarei, Jasem Sharifi, Hamid Mirzazadeh, Ali Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran |
title | Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran |
title_full | Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran |
title_fullStr | Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran |
title_full_unstemmed | Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran |
title_short | Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran |
title_sort | proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure hiv and hcv incidence in kerman, iran |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017615/ https://www.ncbi.nlm.nih.gov/pubmed/33794943 http://dx.doi.org/10.1186/s13011-021-00368-9 |
work_keys_str_mv | AT mousavianghazal proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran AT ghalekhaninima proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran AT tavakolifatemeh proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran AT mcfarlandwilli proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran AT shahesmaeiliarmita proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran AT sharafiheidar proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran AT khezrimehrdad proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran AT mehmandoostsoheil proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran AT zareijasem proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran AT sharifihamid proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran AT mirzazadehali proportionandreasonsforlosstofollowupinacohortstudyofpeoplewhoinjectdrugstomeasurehivandhcvincidenceinkermaniran |